1. Home
  2. PTRN vs HTFL Comparison

PTRN vs HTFL Comparison

Compare PTRN & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PTRN
  • HTFL
  • Stock Information
  • Founded
  • PTRN 2013
  • HTFL 2007
  • Country
  • PTRN United States
  • HTFL United States
  • Employees
  • PTRN N/A
  • HTFL N/A
  • Industry
  • PTRN Catalog/Specialty Distribution
  • HTFL
  • Sector
  • PTRN Consumer Discretionary
  • HTFL
  • Exchange
  • PTRN Nasdaq
  • HTFL Nasdaq
  • Market Cap
  • PTRN 2.5B
  • HTFL 2.8B
  • IPO Year
  • PTRN 2025
  • HTFL 2025
  • Fundamental
  • Price
  • PTRN $16.91
  • HTFL $37.52
  • Analyst Decision
  • PTRN Strong Buy
  • HTFL Strong Buy
  • Analyst Count
  • PTRN 10
  • HTFL 4
  • Target Price
  • PTRN $18.11
  • HTFL $37.00
  • AVG Volume (30 Days)
  • PTRN 872.5K
  • HTFL 319.9K
  • Earning Date
  • PTRN 11-05-2025
  • HTFL 11-12-2025
  • Dividend Yield
  • PTRN N/A
  • HTFL N/A
  • EPS Growth
  • PTRN N/A
  • HTFL N/A
  • EPS
  • PTRN 0.57
  • HTFL N/A
  • Revenue
  • PTRN $2,093,416,000.00
  • HTFL $148,540,000.00
  • Revenue This Year
  • PTRN $33.90
  • HTFL $34.51
  • Revenue Next Year
  • PTRN $23.45
  • HTFL $24.58
  • P/E Ratio
  • PTRN $29.67
  • HTFL N/A
  • Revenue Growth
  • PTRN 111.34
  • HTFL 44.32
  • 52 Week Low
  • PTRN $12.00
  • HTFL $26.56
  • 52 Week High
  • PTRN $18.95
  • HTFL $41.22
  • Technical
  • Relative Strength Index (RSI)
  • PTRN N/A
  • HTFL N/A
  • Support Level
  • PTRN N/A
  • HTFL N/A
  • Resistance Level
  • PTRN N/A
  • HTFL N/A
  • Average True Range (ATR)
  • PTRN 0.00
  • HTFL 0.00
  • MACD
  • PTRN 0.00
  • HTFL 0.00
  • Stochastic Oscillator
  • PTRN 0.00
  • HTFL 0.00

About HTFL Heartflow Inc. Common Stock

HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.

Share on Social Networks: